
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a clinical-stage biotechnology company that is leveraging AI and ML for the development of precision antibodies to treat obesity, cardiometabolic, and cardiopulmonary diseases. With multiple early clinical readouts expected in the next 12-18 months and an intriguing pipeline of novel antibodies, the Company's stock has a positive outlook, supported by its recent preclinical data for IBIO-610 and regulatory approval for IBIO-600. However, there are risks associated with investing in a clinical-stage company, including significant competition and the potential for IP infringement suits.
Bears say
iBio is a clinical-stage biotechnology company that is heavily relying on AI and ML for the development of precision antibodies to treat obesity and other diseases. However, the Company has a number of fundamental weaknesses, including a lack of current revenue-generating products, a history of cash burn, and the need to raise additional capital in the future. These factors, coupled with the risks associated with clinical trials and patent protection, make us hesitant to recommend a positive outlook for the stock.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares